Hematoma (Blood Collection)

In short: Hematoma is a palpable, purple-red three-dimensional lesion that occurs when blood accumulates in a closed cavity after injury to the vessel wall. It is seen after filler injection (facial artery laceration), threadlift and surgical interventions in aesthetic procedures. Unlike ecchymosis, it is dull and palpable. Timeline: 0-24 hours blood accumulation, 3-7 days organized clot (hardening), 1-3 months healing-resolution. Treatment: cold for the first 48 hours, then hot compress, topical Arnica/vitamin K, organized hematomas aspiration and pulse-dye laser candidate. Red flags — pulsatile (arteriovenous fistula), expanding (major bleeding), vision change after periorbital filler, severe pain — require urgent intervention.

Description

Hematoma (Greek "haima" = blood, "stasis" = stop) is a limited mass lesion in a closed cavity, where blood accumulates in the extravascular space (outside the vessel) as a result of the disruption of the integrity of the vessel wall and forms an organized clot and fibrous capsule. While the ICD-10 classification is coded as traumatic hematoma (T14.0, superficial traumatic iniury) and soft tissue hematoma (M79.81), iatrogenic hematoma is included in the postprocedural complication (L76.3) heading. Pathological diagnosis is to show extravascular blood accumulation (coagulum) and coagulated blood (organized clot) surrounded by fibrin clot.

Clinically, the hematoma is a "palpable" mass and may show signs of fluctuation. The main difference from ecchymosis (bruising, contusion) is that ecchymosis is a flat and two-dimensional color change on the skin surface, while hematoma is a blunt and three-dimensional, palpable node. In aesthetic medicine, hematomas are often associated with vascular injury—especially facial arteries and veins (angular artery, superior labial artery, supratrochlear artery). Over time, the hematoma progresses from the organized clot stage (1-2 weeks) to the fibrous capsule stage (3-4 weeks) and the residual discoloration stage (3-6 months).

Pathogenesis and Mechanism

The mechanism of hematoma formation begins with a traumatic or iatrogenic injury to the vascular wall and progresses through the hemostasis cascade (blood clotting mechanism) and organizational phases.

1. Vascular Injury

Vessel wall integration is disrupted as a result of intima (inner layer) perforation, media (middle muscular layer) tear, or even adventitia (outer layer) injury with the injection needle or cannula. Particularly the facial arteries and veins—angular artery (inside the eye), supratrochlear artery (glabellar region, 1.5 cm medial-midline), superior labial artery (midline of the upper lip)—are at risk.

2. Blood Extravasation

Blood immediately begins to flow from the injured vessel to the surrounding tissue (subcutaneous, intramuscular, subperiosteal, etc. areas) with arterial or venous pressure. Arterial extravasation (fast, high pressure) produces a more severe hematoma than venous extravasation (slow, low pressure) and can often be more blunt and pulsatile.

3. Hemostasis Cascade

Extravascular blood follows the path of platelet activation → fibrin polymerization → clot formation. While the blood clot is initially temporary and "soft", it hardens within minutes by fibrin cross-linking and platelet retraction.

4. Organization and Fibrous Capsule

The clot is organized by fibroblasts (fibrin-producing cells) and endothelial cells in the surrounding tissues. Macrophage infiltration produces hemosiderin (iron deposit) and ferritin. Within 2-4 weeks, the organized clot is surrounded by a fibrous capsule. This capsule is the main structural change in the healing pathway of the hematoma.

5. Residual Coloration and Reabsorption

Hemoglobin metabolism: Yellow-green-yellow color transformation of blood (hematoma color change) results from the degradation of hemoglobin → heme → biliverdin → bilirubin. Macrophages move to the hematoma area and phagocytose blood pigments. In 3-6 months, most hematomas are resorbed through the lymphatic and blood circulation; Permanent color change (dyspigmentation) may remain, albeit slightly.

Risk Factors

Patient Risk Factors:

• Anticoagulation and Antiplatelet Therapy: Warfarin, direct oral anticoagulants (DOACs; apixaban, rivaroxaban), aspirin, clopidogrel (Plavix), prasugrel — increase the incidence of hematomas and make the hematoma heavier.
• Vitamin/Supplement Usage: Fish oil (omega-3), vitamin E, ginseng, resveratrol, ginkgo biloba, Chinese parsley — may increase your bleeding propolis with antiplatelet activity.
• Thrombocytopenia: Low platelet count (<100,000/μL) → increased risk and size of hematoma.
• Advanced Age (>65 years): In elderly patients, capillary fragility increases, skin elasticity decreases, and bleeding tendency is high.
• Gender (Female Domination): Estrogen and estrogen-like hormones can increase capillary permeability; amenorrhea, oral contraceptives, HRT (hormone replacement therapy) may be effective.
• Fitzpatrick Skin Type III+: Post-inflammatory pigmentation (PIP) may make hematoma discoloration more noticeable on darker skin.
• Thin Skin Thickness: In patients with a thin subcutaneous fat layer, the vessels are more open to external factors.
• Alcohol Use: Alcohol's increased anticoagulation, platelet inhibition and vasodilatation effects potentiate hematoma.

Procedure Risk Factors:

• Filler Injection: Facial artery/vein laceration, needle trauma; especially tear trough (under eye), glabellar, nasolabial fold risk areas.
• Threadlift: Larger cannulas (19-21G) and wide dissection paths → higher risk of hematoma.
• Surgical Procedures: Face-lift, abdominoplasty, liposuction, rhinoplasty — subcutaneous fat cavity cavity and vascular trauma → extensive hematoma.
• Laser and Radiofrequency: Lower risk; Small capillarity hematoma may form through hemoglobin absorption, thermal necrosis.

Clinical Appearance and Diagnosis

Supercutaneous Hematoma (Superficial, Palpable): In areas such as under eyes, cheeks, lips, forehead; palpable mass, fluctuation (+) is present. Color: red-purple in the first 24 hours, dark purple in 2-5 days, blue in 5-7 days, green in 7-10 days, yellow and brown in 10-14 days. It is accompanied by swelling and pain. Inch retention and discomfort are patient complaints.

Subcutaneous Hematoma (Deep, Closed): It can be found in the muscle layer such as the masseter, chin edge, and under the lip. Slight swelling and stiffness on the face; dull, nonfluctuant, painful heaviness underneath. Superficial findings are minimal.

Submuscular Hematoma (Surgical): After face-lift, neck lift, deep hematoma under the muscle (retromandibular, submuscular plane). Minimal appearance on the skin; complaints of pain, stiffness, serome (fluid accumulation). High risk of complications (infection, pressure necrosis).

Physical Findings:

• Palpation: Crusty, hard or fluctuant; Increased pain on finger pressure or discoloration (bruising) more pronounced/selected depending on depth.
• Fluctuation Finding: If there is fluid accumulation within the hematoma (perhaps a serum component), movement will be felt with finger pressure (positive fluctuance = indication for urgent aspiration).
• Reduction Light: LED/turning test: hematoma density, deep/massive, if the tooth blocks light passage; If they pass, superficial/seroma index.
• Pulsatility: Pulsatile hematoma = sign of arteriovenous fistula or pseudoaneurysm. Sign of EMERGENCY.

Viewing (if necessary): Ultrasound, MRI — deep hematoma, seroma-hematoma differentiation, suspicion of vascular complications.

Timeline and Stages of Recovery

0-24 Hours (Acute Period): Blood accumulation, hematoma formation. Swelling (edema) and pain begin immediately after the injury. Maximum expansion in the first 6 hours. The color is red-purple. Patients feel a "sudden burst".

24-48 Hours (Early Organized Period): Fibrin cross-linking begins, clot hardening. Color purple-red-blue transition. The swelling begins to decrease; pain is still significant (4-5/10 pain scale).

3-7 Days (Early Phase of Organization): The clot becomes organized and hard (indurated). The color turns to blue-green tones. Fluctuation begins (fluid is resorbed). Stiffness/palpation pain may increase (mesenchymal irritation).

7-14 Days (Organization Middle Phase): Hematoma size is significantly reduced. Coloration green-yellow transition. Fibroblast infiltration and capsule formation. Mild hematomas (30-50%) resolve completely during this period.

2-4 Weeks (Fibrous Capsule Phase): The clot is encapsulated in fibrous tissues. Color yellow-brown. The gross hematoma is still palpable; Aspiration can be performed during this period (due to fluid consistency).

1-3 Months (Resident Coloration and Reabsorption): 80-90% of hematoma size disappears. Permanent color change (purple hue) begins in the wee hours. The fibrous capsule turns into a thin, collagen-rich layer over time and is absorbed. Macrophage activity hemosiderin phagocytosis.

3-6 Months (Long Term Residual): Most hematomas disappear. In some patients, subtle color change (hemosiderin staining — pale pink/red) may persist for 6-12 months.

Home Care and First Response

RICE Protocol (First 48 Hours):

• Rest: Restrict movement of the injured area. Reducing facial movements (use the chin less, avoid smiling).
• Ice (Cold): 15 minutes × hourly cold compress (ice, ice pack, cold gel) in the first 24 hours. Vasoconstriction → decrease in blood accumulation. Do not continue after 48 hours (slows healing).
• Compression: Artificial pressure tape (elastic bandage) option; but facial compression is often impractical (hair, glasses, massage difficulty).
• Elevation: Keeping the head elevated on 2-3 pillows during sleep. Aid fluid resorption using gravity.

Topical Treatment:

• Arnica Montana Gel: Phytotherapeutic agent for hematoma and ecchymosis. Religiously 3-4 times a day, the first 7-10 days. While popular among people, the scientific evidence is moderate (some meta-analyses report 10-15% effectiveness). No side effects.
• Vitamin K Cream (Auriderm XO, phylloquinone): Reduction of ecchymosis-hematoma by supporting the capillary mechanism. It is used for 2-3 weeks. Efficacy is similar to or slightly higher than Arnica.
• Hirudoid Cream (Heparin-containing): Topical heparin (mucopolysaccharide) may accelerate hematoma healing. On the face 2-3 times a day, 2-3 weeks.

Systemic Treatment:

• Pain Control: Acetaminophen (Tylenol) 500-650 mg × 3-4 hourly is preferred (avoid NSAIDs—increased risk of bleeding). Codeine combination for severe pain (inability to sleep).
• Bromelain (Pineapple Enzyme): Anti-inflammatory proteolytic enzyme. 500-1000 mg/day, 7-14 days. Hematoma resolution may be slightly accelerated; The evidence is moderate.
• Alopurinol/Xanthine Oxidase Inhibitor: Some sources recommend it to accelerate hematoma color change; but routine is not recommended.

After 48 Hours — Hot Treatment: Warm compress, warm shower, light massage (endomassage). Increased circulation, acceleration of hematoma resorption.

Applying for a Doctor - When

Red Flag Symptoms — URGENT:

• Pulsatile Hematoma: If pulsation is felt → pseudoaneurysm or arteriovenous fistula. Emergency doppler ultrasonography and vascular surgeon consultation.
• Expanding Hematoma (Growth continues in the first 48 hours): Active bleeding continues. Surgical drainage may be required.
• Vision Change After Periorbital Filler: Risk of retinal artery occlusion if the hematoma spreads retrobulbarly (behind the eye). Emergency ophthalmology consultation. Vision loss — hyperurgency.
• Intense Pain (8+/10 Pain Scale): It may be a sign of compartment syndrome, infection, or vascular occlusion.
• Heat Increase, Temperature (>38.5°C): Infection. Antibiotics and culture are required.
• Black, Necrotic Skin Color (Eschar): Vascular occlusion, tissue death (necrosis). Emergency response.

Routine Doctor Visit Indicators:

• Still Large Hematoma After 2 Weeks: Aspiration (needle aspiration, with a sterile fine needle) can be performed.
• Permanent Coloration After 1 Month: Starting pulse-dye laser or IPL treatment.
• Seroma Development: If the hematoma has turned into a fluid area (seroma), aspiration or drainage may be required.

Pharmacotherapy and Medical Treatment

Aspiration (Needle Aspiration): Organized hematoma, aspiration with a sterile fine needle (27-30G) after 2-3 weeks. Fluctuant hematoma = candidate for aspiration. Compress after the procedure for 24 hours. The risk of infection is very low (<0.1%) with proper asepsis.

Surgical Drainage: Large, expanding hematomas where hemostasis cannot be achieved — open drainage, saline irrigation, bleeders cauterization, drain line placement (48-72 hours). Expanding is urgent in periorbital or retrobulbar hematoma.

Hyaluronidase (HA Filler Complications): If the hematoma has developed after HA filler injection, injection of hyaluronidase (150-300 IU regionally, 500-1500 IU in cases of suspicion of vascular occlusion) to the same area can accelerate hematoma healing. Hyaluronidase improves lymphatic/vascular absorption of blood and seroma.

Pulse-Dye Laser (PDL — 595 nm): FDA-cleared device (such as Candela V-Beam) for the treatment of hematoma discoloration. Hemoglobin-specific wavelength, oxyhemoglobin and deoxyhemoglobin absorption. In the colored phase of the hematoma (purple-green-yellow), 2-3 sessions with an interval of 1-2 weeks. Efficacy 60-80%. Post-treatment purpura (dark purple) may remain for 7-10 days. Caution on dark skin (Fitzpatrick IV+) due to the risk of hyperpimentation.

Intense Pulsed Light (IPL): Broad spectrum (500-1200 nm), less sacred than PDL; Optional for hematoma treatment (discoloration). Efficacy is lower than PDL.

Topical Steroid (Cream/Gel): Triamcinolone acetonide 0.1% topical, 2-3 weeks. Inflammation reduction, healing acceleration.

Silicone Gel/Pad: Post-hematoma scar prevention (rare); If there is persistent discoloration, silicone pad heavy therapy (pressure therapy).

Hyperbaric Oxygen (HBO): If there is a sign of retrobulbar hematoma or vascular occlusion, increased oxygen saturation, ischemia reversal. Access and cost limiting.

Prevention Strategies

Preoperative Preparation (7 Days Before):

• Antiplatelet/Anticoagulant Cut-off: Aspirin, NSAID, warfarin, clopidogrel → discontinuation for 7 days with physician's approval. Discontinuation of DOACs with expert advice. (Reliability in emergency medicine: INR control, bridging anticoagulation evaluation.)
• Reinforcement Cutting: Discontinue fish oil, vitamin E, ginseng, resveratrol 5-7 days ago.
• Starting Vitamin K: Phylloquinone (K1) 0.5-1 mg/day, if started 7 days before, can support capillary integration.
• Arnica Montana 200CH (Homeopathy): 3 doses × day, last 3 days. The evidence is modest but popular and harmless.

Perioperative Technique:

• Cannula vs Needle: The use of a 27G cannula (instead of a needle) reduces the incidence of hematoma by 80%. Tip flexibility, less vascular trauma.
• Low Injection Pressure: Avoiding rapid bolus injection (high pressure); slow, controlled injection.
• Aspire + Inject Technique: The physician withdraws the needle/cannula, aspirates (intravenously?) → injects. The risk of vascular entry is reduced.
• Topical Thrombex/Vitamin K: Apply topical hemostatic agent to the dermis surface for 5-10 minutes before the procedure.

Postoperative Care (First 48 Hours):

• Cold Compress: 15 minutes per hour, first 48 hours. Vasoconstriction.
• Head Elevation: Head high (2-3 pillows) during sleep. Gravitational venous drainage.
• Activity Restriction: Avoid exercise, sauna, alcohol for 48-72 hours. Increased vasodilation.
• Avoid Local Massage for the First 24 Hours. Risk of hematoma trauma.

Related Aesthetic Procedures — Risk Profiles

Filler Injection (High Risk): Facial artery-vein laceration → hematoma 3-5% incidence. Tear trough, glabellar, nasolabial fold high risk. It decreases to 1% with the Cannula technique.

Threadlift (Medium-High Risk): Large needles, dissection → hematoma 5-8%. Submental, malar lift risk.

Botox (Low Risk): Fine 30-32G needle, intramuscular injection; Vascular trauma is rare. Ecchymosis 1-2% (hematoma less than 0.1%).

Laser/Radiofrequency (Very Low Risk): HIFU, RF, fractionated laser — thermal necrosis > vessel rupture rare.

Surgery (High Risk): Face-lift, rhinoplasty, liposuction — subcutaneous dissection area → hematoma 5-20% incidence (depending on site). The use of drain pipe reduces the risk.

Related Terms

Hematoma treatment and management is closely related to the following medical aesthetics terms:

• Ecchymosis (bruising, contusion) — Flat, superficial blood discoloration, etc. hematoma palpable mass.
• Swelling (Edema, Edema) — Inflammatory fluid accumulation accompanying hematoma.
• Keloid (Hypertrophic Scar) — Hematoma fibrous capsule, unusual fibroblast reaction.
• Postoperative Care Protocol — Hematoma prevention and early management.
• Hyaluronidase (HA Reversal) — HA filler hematoma treatment.
• Filler (Dermal Filler) — Hematoma primary trigger.
• Lip Filler — Hematoma risk area.
• Botox (BoNT-A) — Combination therapy; The risk of hematoma is low.

Frequently Asked Questions

1. What is the difference between hematoma and ecchymosis?

   Ecchymosis is a flat color change (two-dimensional) on the skin surface. A hematoma is a palpable mass (three-dimensional, palpable) that occurs when blood accumulates in a closed space. The hematoma usually stays deeper, thicker and longer.

2. How long does it take for a hematoma to disappear?

   Mild hematoma usually resolves within 7-14 days. Medium-sized hematoma may remain for 2-4 weeks. Large hematomas may persist for 3-6 months, but 80% disappear within 6-8 weeks. Permanent color change may take 6-12 months.

3. Is hematoma aspiration safe?

   Yes. Organized hematomas (beyond 2-3 weeks), fluctuant and palpable are candidates for aspiration with a sterile fine needle (27-30G). The risk of infection is very low (<0.1%) with proper asepsis. Earlier aspiration (in the first 48 hours) increases the risk of bleeding.

4. Can a hematoma become infected?

   Rare but possible. Most often secondary to penetrating trauma, an open wound, or from bacterial contamination during the procedure. A visit to the doctor is necessary when the temperature and haze appear. Antibiotics and drainage may be required.

5. What does pulsatile hematoma mean and why is it dangerous?

   Pulsatile hematoma indicates arteriovenous fistula (abnormal connection between vessels) or pseudoaneurysm (partial rupture of the vessel wall). If pulsation is felt, urgent Doppler ultrasound and vascular surgeon consultation is required. If neglected, it may lead to serious complications (bleeding, necrosis).

6. What are the emergency interventions after a hematoma occurs?

   Cold compress in the first 24 hours (15 min × hourly). Start using warm compresses after 48 hours. Arnica, vitamin K cream topical, acetaminophen for pain. If there are red flags (pulsatile, expanding, vision change, temperature), see a doctor immediately. Organized hematoma aspiration after 2-3 weeks.

7. How can I reduce the risk of hematoma after filler?

   Stop aspirin/NSAID/supplement (fish oil, vitamin E) 7 days before. Arnica 3 days ago. Use of cannula in procedure (80% reduction). Slow, low-pressure injection. Aspirate + inject technique. Then cold + elevated head.

8. Does pulse-dye laser really solve hematoma discoloration?

   Yes, PDL (595 nm) is hemoglobin-specific. 2-3 sessions with 1-2 week intervals during the hematoma colored phase (2-4 weeks). Efficacy 60-80%. Dark skin (Fitzpatrick IV+) has a risk of hyperpimentation. Post-treatment purpura (dark purple) 7-10 days is normal.

9. I use warfarin — is there a high risk of hematoma?

   Yes. Anticoagulation (INR > 2) increases the risk and size of hematoma. Pre-procedure INR test and hematology/physician consultation are mandatory. In some cases, the procedure can be postponed for 2-4 weeks. Bridging anticoagulation (DOAC) evaluation.

10. What is the symptom of retrobulbar hematoma (behind the eye)?

    If the hematoma spreads behind the eye (retrobulbar): vision loss, eye pain, limitation of eye movement (ophthalmoplegia), proptosis (progress of the eye). Urgent ophthalmologist consultation and MRI are required. Risk of compartment syndrome; lateral canthotomy may be required (pressure relief).

Op. Dr. Hamza Gemici Comment

Hematoma is one of the most common but usually mild complications of aesthetic procedures. In our 25 years of practice, the success of hematoma management is based on correct preoperative preparation, technical care (cannula, aspire-inject) and postoperative cold compress discipline. Most hematomas disappear on their own within 2-4 weeks; Once large, fluctuant hematomas are organized (2-3 weeks), sterile fine needle aspiration provides excellent results. Pulse-dye laser is the gold standard for hematoma discoloration treatment — PDL session starts after 2-4 weeks. The most critical point is to recognize the red flags: pulsatile hematoma (arteriovenous fistula), expanding hematoma (major bleeding), vision change after periorbital filler (retrobulbar hematoma), severe pain/heat (infection or compartment syndrome). These findings, which are indicative of the region, require urgent and undelayed evaluation. Preoperative INR and hematology consultation are mandatory in patients using warfarin, DOAC, and aspirin. Every clinician should keep the hematoma emergency protocol (cold compress, head elevation, hyaluronidase optional, emergency drainage if necessary) in the back pocket.

Resources

1. DeLorenzi C. "Complications of dermal fillers, impart and management." Dermatologic Surgery
   Authors: DeLorenzi C
   Publisher: PubMed / Dermatologic Surgery
   Year: 2017
   URL: https://pubmed.ncbi.nlm.nih.gov/27191199/
2. Beleznay K, Carruthers JDA, Humphrey S, et al. "Updated Understanding of the Mechanism of Action of Hyaluronic Acid Fillers." Dermatologic Surgery
   Authors: Beleznay K, Carruthers JDA, Humphrey S, et al.
   Publisher: PubMed / Dermatologic Surgery
   Year: 2019
   URL: https://pubmed.ncbi.nlm.nih.gov/30865016/
3. Urdiales-Gálvez F, Delgado NE, Figueiredo V, et al. "Soft Tissue Filler Safety: A Review of Adverse Events by Category." American Journal of Clinical Dermatology
   Authors: Urdiales-Gálvez F, Delgado NE, Figueiredo V, et al.
   Publisher: PubMed / Aesthetic Plastic Surgery
   Year: 2017
   URL: https://pubmed.ncbi.nlm.nih.gov/28643149/
4. Alam M, Gladstone H, Kramer E, et al. "ASDS Guidelines of Care: Adverse Events Associated with Dermal Fillers." Journal of the American Academy of Dermatology
   Authors: Alam M, Gladstone H, Kramer E, et al.
   Publisher: PubMed / Journal of the American Academy of Dermatology
   Year: 2015
   URL: https://pubmed.ncbi.nlm.nih.gov/26068099/
5. Pittler MH, Abbot NC, Harkness EF, et al. "Arnica for bruising and soreness: a systematic review of randomized controlled trials." British Journal of Sports Medicine (Cochrane Review)
   Authors: Pittler MH, Abbot NC, Harkness EF, et al.
   Publisher: Cochrane / British Journal of Sports Medicine
   Year: 2016 (Cochrane Database update)
   URL: https://www.cochranelibrary.com/
6. Sykes JM, Katz T, Yung R, et al. "Treatment of Dermal Filler Complications: Current Best Practice." Aesthetic Surgery Journal
   Authors: Sykes JM, Katz T, Yung R, et al.
   Publisher: PubMed / Aesthetic Surgery Journal
   Year: 2020
   URL: https://pubmed.ncbi.nlm.nih.gov/32627691/

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici